News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Grants "Orphan Drug" Designation For Genervon’s Breakthrough Multi-Target ALS Bio-Drug GM604



3/3/2014 8:41:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PASADENA, Calif.--(BUSINESS WIRE)--Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted an “orphan drug” designation to Genervon’s GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS). The FDA also granted GM604 a “fast-track” designation for ALS in 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES